Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 175, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.addr.2021.113831
Keywords
Fibrosis; Drug targeting; Nanomedicine; Imaging; Atherosclerosis; Cardiovascular disease; Cancer; Diabetes; Liver; Viral infection
Categories
Funding
- European Research Council (ERC: Meta-Targeting) [864121]
- European Union (European Fund for Regional Development) : TAKTIRA [EFRE0801767]
- German Research Foundation (DFG) [LA 2937/41, SH 1223/11, SFB/TRR57, SFB1066, GRK/RTG2375, 331065168]
- German Federal Ministry of Education and Research (BMBF: PPTNBC) [16GW 0319K]
- Excellence Strategy of the Federal Government [EXSSFOPSF580]
- Italian Association for Cancer Research (AIRC) fellowship
- Singapore Ministry of Health's National Medical Research Council [NMRC/OFYIRG/0081/2018]
- National University of Singapore NanoNASH Program [NUHSRO/2020/002/NanoNash/LOA]
- European Research Council (ERC) [864121] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Fibrosis is a common factor in various pathologies, affecting disease progression, drug delivery efficiency, and therapy outcomes. This article summarizes therapeutic and diagnostic strategies for fibrosis in different diseases, focusing on anti-fibrotic targets and nanomedicine formulations. The role of medical imaging in diagnosing and monitoring fibrotic disorders is also discussed.
Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies. (c) 2021 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available